

**Intrauterine autologous platelet-rich plasma for thin endometrium in clomiphene citrate–  
induced cycles: a pre- and post-interventional study.**

**ABSTRACT:**

**Background:** Clomiphene citrate (CC) is first-line therapy for World Health Organization type II anovulation, but its anti-oestrogenic action often leaves the endometrium thin, underlying the gap between its high ovulation rates and far lower conception rates. Autologous platelet-rich plasma (PRP), rich in growth factors, has been proposed to rescue such cycles.

**Objectives:** To determine whether intrauterine PRP increases endometrial thickness in women with a persistently thin endometrium on CC, and to record the clinical pregnancy rate.

**Methods:** This pre- and post-interventional study was conducted in a tertiary teaching hospital in central India. Forty infertile women with endometrial thickness under 7 mm on the day of trigger were enrolled. CC 50 mg was given daily for five days from day 2, and 1 mL of autologous PRP was instilled intrauterine on days 8 and 10 of the subsequent induced cycle. Thickness was measured sonographically before and after intervention. Paired t-tests and the chi-square test were applied ( $p < 0.05$ ).

**Results:** Mean age was  $27.62 \pm 3.54$  years and 72.5% had primary infertility. Mean endometrial thickness raised from  $5.10 \pm 1.19$  mm to  $7.43 \pm 0.73$  mm, a gain of 2.33 mm ( $p < 0.001$ ). The increase was significant within every follicle-stimulating hormone, anti-Müllerian hormone, thyroid, prolactin and body mass index subgroup. Gains were largest where the endometrium was thinnest, averaging 4.35 mm below 3 mm. Six women (15.0%) conceived. No adverse events occurred.

**Conclusion:** Intrauterine PRP produced a consistent, significant increase in endometrial thickness across all subgroups, greatest in the thinnest endometria. It was simple and well tolerated, but the modest pregnancy rate and uncontrolled design mean randomised comparison remains necessary.

**Keywords:** platelet-rich plasma; thin endometrium; clomiphene citrate; ovulation induction; endometrial receptivity; infertility

## INTRODUCTION

Infertility affects roughly one couple in eight worldwide, and disordered ovulation accounts for close to a fifth of these cases.<sup>1</sup> The great majority of anovulatory women have gonadotrophin concentrations within the reference range and are classified as World Health Organization type II, a group dominated by polycystic ovary syndrome and characterised clinically by oligomenorrhoea or amenorrhoea.<sup>2,3</sup> For more than six decades clomiphene citrate has been the drug of first resort in this population.<sup>4</sup> Acting as a selective oestrogen receptor modulator, it blocks hypothalamic oestrogen receptors, releases the pituitary from negative feedback and provokes the follicle-stimulating hormone surge that drives folliculogenesis.<sup>5</sup>

The difficulty is that ovulation and conception do not follow one another as closely as might be expected. Clomiphene induces ovulation in 60% to 85% of treated women, yet cumulative pregnancy rates after six cycles remain in the region of 10% to 20%.<sup>6</sup> This discordance has long been attributed to the very property that makes the drug effective centrally. Because clomiphene occupies oestrogen receptors indiscriminately, its action at the endometrium and cervix is antagonistic rather than agonistic, blunting proliferation of the functionalis and reducing uterine perfusion at precisely the point in the cycle when both are needed.<sup>7</sup>

Endometrial thickness has become the practical surrogate for receptivity in this setting. A minimum of 7 mm on the day of trigger is widely accepted as the threshold below which implantation becomes substantially less likely,<sup>8</sup> and thin endometrium has been reported in anywhere between 15% and half of clomiphene cycles depending on the population and the criteria applied.<sup>9</sup> The clinical consequence is a cycle that is technically successful — a dominant follicle, a documented ovulation — but reproductively futile.

A considerable number of adjuvants have been tried in an attempt to close this gap, among them supplementary oestrogen, low-dose aspirin, vaginal sildenafil, pentoxifylline and granulocyte colony-stimulating factor.<sup>10</sup> None has proved reliably effective, and a substantial minority of women remain refractory to all of them. This therapeutic impasse has directed attention towards regenerative approaches.

Autologous platelet-rich plasma is prepared by centrifuging the patient's own blood to concentrate the platelet fraction. Activated platelets release a cocktail of mediators — vascular endothelial growth factor, platelet-derived growth factor, epidermal growth factor and transforming growth factor among them — that together promote angiogenesis, cellular proliferation and matrix remodelling.<sup>11,12</sup> Because the preparation is derived from the patient, questions of immunogenicity and disease transmission largely fall away. The first report of intrauterine PRP for thin endometrium appeared in 2015,<sup>13</sup> and subsequent series and trials have described gains in thickness and, less consistently, in pregnancy rates.<sup>14,15</sup>

Most of this literature, however, concerns frozen-thawed embryo transfer and in vitro fertilisation, where the endometrium is prepared with exogenous hormones. Evidence drawn specifically from clomiphene-induced cycles, in which the mechanism of thinning is pharmacological antagonism rather than atrophy or scarring, remains comparatively

sparse.<sup>16,17</sup> The present study was undertaken to address that gap, examining whether intrauterine PRP can restore endometrial thickness in women whose endometrium fails to develop adequately on clomiphene, and whether such restoration translates into pregnancy.

## **MATERIALS AND METHODS**

This pre- and post-interventional study was conducted in the Department of Obstetrics and Gynaecology of a tertiary teaching hospital in Raipur, Chhattisgarh, India. The protocol was approved by the Institutional Ethics Committee and written informed consent, explained in the participant's own language, was obtained before enrolment.

Infertile women attending the outpatient clinic who had been induced with clomiphene citrate and whose endometrial thickness measured less than 7 mm on the day of trigger were eligible. Women who declined consent were excluded. Because no comparable published series was available from which to derive an effect size, complete enumeration sampling was used and recruitment continued until 40 participants had been enrolled.

At enrolment, age, weight, body mass index, duration of marriage, presenting complaint, menstrual pattern and coexisting medical disorders were recorded. Serum thyroid-stimulating hormone, anti-Müllerian hormone, follicle-stimulating hormone and prolactin were measured, and the partner's semen analysed. Baseline ultrasonography documented endometrial thickness, antral follicle number and dominant follicle size.

Each participant received clomiphene citrate 50 mg daily for five days from day 2. In the subsequent induced cycle, 1 mL of autologous PRP, prepared by centrifugation of autologous venous blood in the institutional laboratory, was instilled into the uterine cavity through an insemination catheter under aseptic conditions on days 8 and 10. Endometrial thickness was

reassessed on day 8, on the day of trigger and two days after ovulation. Participants were followed until a positive urine pregnancy test, clinical evidence of pregnancy, or the seventh day after the missed period.

Data were compiled in Microsoft Excel 2019 and analysed in SPSS version 23.0. Categorical variables are presented as frequency and percentage, continuous variables as mean  $\pm$  standard deviation. Paired t-tests were used for within-subject comparison of endometrial thickness and the chi-square test for categorical associations. A two-tailed p-value below 0.05 was taken as significant.

## RESULTS

Forty women completed the protocol. Their baseline demographic and clinical characteristics are summarised in Table 1. The cohort was young, with a mean age of  $27.62 \pm 3.54$  years and a range of 22 to 38 years, and three-quarters were between 21 and 30 years old. Mean body weight was  $54.72 \pm 8.47$  kg and two-thirds had a body mass index within the normal range. Three-quarters had been married for five years or less. Primary infertility predominated, and all but one woman menstruated regularly.

**Table 1. Baseline demographic and clinical profile of participants (n = 40)**

| Characteristic | Category      | n                | %           |
|----------------|---------------|------------------|-------------|
| Age (years)    | 21–30         | 30               | 75.0        |
|                | 31–40         | 6                | 15.0        |
|                | Mean $\pm$ SD | $27.62 \pm 3.54$ | Range 22–38 |
| Weight (kg)    | 41–60         | 33               | 82.5        |

|                              |                           |                  |             |
|------------------------------|---------------------------|------------------|-------------|
|                              | 61–80                     | 6                | 15.0        |
|                              | > 80                      | 1                | 2.5         |
|                              | Mean $\pm$ SD             | 54.72 $\pm$ 8.47 | Range 43–83 |
| Body mass index              | Normal                    | 27               | 67.5        |
|                              | Overweight                | 9                | 22.5        |
|                              | Obese                     | 4                | 10.0        |
| Duration of marriage (years) | 1–5                       | 30               | 75.0        |
|                              | 6–10                      | 9                | 22.5        |
|                              | > 10                      | 1                | 2.5         |
| Type of infertility          | Primary                   | 29               | 72.5        |
|                              | Secondary                 | 11               | 27.5        |
| Menstrual pattern            | Regular                   | 39               | 97.5        |
|                              | Irregular                 | 1                | 2.5         |
| Coexisting disorder          | Hypothyroidism            | 4                | 10.0        |
|                              | Hyperprolactinaemia       | 2                | 5.0         |
|                              | Polycystic ovary syndrome | 1                | 2.5         |
|                              | Sickle cell trait         | 1                | 2.5         |

105 The endocrine profile of the cohort is shown in Table 2. Ovarian reserve was broadly preserved:  
 106 two-thirds had an anti-Müllerian hormone concentration between 1.5 and 3.5 ng/mL and only  
 107 five women fell below 1.5 ng/mL. Follicle-stimulating hormone lay between 5 and 10 mIU/mL  
 108 in just over two-thirds. Mild thyroid and prolactin abnormalities were present in a minority. The

109 partner's semen analysis was normal in 38 of the 40 couples; the two abnormal samples, one  
 110 showing pyospermia and one reduced motility, were treated before the study cycle. The mean  
 111 antral follicle count was  $8.37 \pm 3.42$ .

112 **Table 2. Baseline endocrine profile and partner semen analysis (n = 40)**

| Parameter                             | Category         | n               | %              |
|---------------------------------------|------------------|-----------------|----------------|
| Thyroid-stimulating hormone (mIU/L)   | $\leq 3$         | 29              | 72.5           |
|                                       | $> 3$            | 11              | 27.5           |
|                                       | Mean $\pm$ SD    | $2.50 \pm 1.41$ | Range 0.4–8.01 |
| Anti-Müllerian hormone (ng/mL)        | $< 1.5$          | 5               | 12.5           |
|                                       | 1.5–3.5          | 26              | 65.0           |
|                                       | $> 3.5$          | 9               | 22.5           |
| Follicle-stimulating hormone (mIU/mL) | $< 5$            | 13              | 32.5           |
|                                       | 5–10             | 27              | 67.5           |
|                                       | Mean $\pm$ SD    | $5.80 \pm 1.69$ | Range 2.25–8.9 |
| Serum prolactin (ng/mL)               | $\leq 28$        | 33              | 82.5           |
|                                       | $> 28$           | 7               | 17.5           |
| Partner semen analysis                | No abnormality   | 38              | 95.0           |
|                                       | Pyospermia       | 1               | 2.5            |
|                                       | Reduced motility | 1               | 2.5            |

The primary outcome is presented in Table 3. Mean endometrial thickness rose from  $5.10 \pm 1.19$  mm before treatment to  $7.43 \pm 0.73$  mm afterwards, an absolute gain of 2.33 mm, and the difference was highly significant on paired analysis ( $p < 0.001$ ). The narrowing of the standard deviation is as notable as the shift in the mean: the post-treatment distribution was appreciably more compact, indicating that the intervention brought outlying endometria towards a common range rather than simply adding a fixed increment to every participant.

Stratification by baseline thickness makes this clearer. Women who began with an endometrium thinner than 3 mm gained an average of 4.35 mm, those in the 3 to 4.9 mm band gained 2.96 mm, and those already between 5 and 7 mm gained 1.85 mm. The response was therefore inversely proportional to the starting thickness, and after treatment every participant reached at least 5 mm.

**Table 3. Endometrial thickness before and after PRP, overall and by baseline stratum (n = 40)**

| Baseline stratum | n (%)      | ET before PRP (mm) | Mean ET after PRP (mm) | Mean gain (mm) | p         |
|------------------|------------|--------------------|------------------------|----------------|-----------|
| Overall cohort   | 40 (100.0) | $5.10 \pm 1.19$    | $7.43 \pm 0.73$        | 2.33           | $< 0.001$ |
| < 3 mm           | 4 (10.0)   | —                  | 6.38                   | 4.35           | $< 0.001$ |
| 3–4.9 mm         | 10 (25.0)  | —                  | 7.19                   | 2.96           |           |
| 5–7 mm           | 26 (65.0)  | —                  | 7.68                   | 1.85           |           |



ET, endometrial thickness; PRP, platelet-rich plasma.

Table 4 shows the response within endocrine and anthropometric subgroups. The increase in endometrial thickness was statistically significant in every stratum examined. Neither ovarian reserve, as reflected by anti-Müllerian hormone, nor basal follicle-stimulating hormone, thyroid status, prolactin concentration or body mass index abolished the effect. Post-treatment thickness clustered tightly between 7.04 and 7.75 mm across all twelve subgroups despite pre-treatment means ranging from 4.33 to 5.75 mm, which again suggests convergence towards a ceiling rather than a uniform additive gain.

**Table 4. Endometrial response by endocrine and anthropometric subgroup (n = 40)**

| Stratifying variable                  | Category | n (%)     | ET before PRP (mm) | ET after PRP (mm) | p       |
|---------------------------------------|----------|-----------|--------------------|-------------------|---------|
| Follicle-stimulating hormone (mIU/mL) | < 5      | 13 (32.5) | 4.33 ± 1.64        | 7.27 ± 0.74       | < 0.001 |
|                                       | 5–10     | 27 (67.5) | 5.40 ± 0.97        | 7.50 ± 0.73       | < 0.001 |
| Anti-Müllerian hormone (ng/mL)        | < 1.5    | 5 (12.5)  | 4.38 ± 1.60        | 7.04 ± 1.19       | 0.0193  |
|                                       | 1.5–3.5  | 26 (65.0) | 5.21 ± 1.20        | 7.50 ± 0.65       | < 0.001 |
|                                       | > 3.5    | 9 (22.5)  | 4.95 ± 1.47        | 7.43 ± 0.71       | 0.0007  |

|                                     |            |              |                 |                 |           |
|-------------------------------------|------------|--------------|-----------------|-----------------|-----------|
| Thyroid-stimulating hormone (mIU/L) | $\leq 3$   | 29<br>(72.5) | $5.10 \pm 1.23$ | $7.75 \pm 0.56$ | $< 0.001$ |
|                                     | $> 3$      | 11<br>(27.5) | $5.03 \pm 1.35$ | $7.31 \pm 0.76$ | $< 0.001$ |
| Serum prolactin (ng/mL)             | $\leq 28$  | 33<br>(82.5) | $5.07 \pm 1.31$ | $7.41 \pm 0.78$ | $< 0.001$ |
|                                     | $> 28$     | 7<br>(17.5)  | $4.94 \pm 1.39$ | $7.50 \pm 0.48$ | 0.0020    |
| Body mass index                     | Normal     | 27<br>(67.5) | $4.87 \pm 1.46$ | $7.40 \pm 0.78$ | $< 0.001$ |
|                                     | Overweight | 9<br>(22.5)  | $5.27 \pm 0.97$ | $7.50 \pm 0.49$ | $< 0.001$ |
|                                     | Obese      | 4<br>(10.0)  | $5.75 \pm 0.23$ | $7.47 \pm 1.02$ | 0.0400    |

ET, endometrial thickness; PRP, platelet-rich plasma.

Cycle outcome is given in Table 5. Six of the 40 women (15.0%) achieved a clinical pregnancy.

No local or systemic adverse effect was recorded in any participant, and no procedure had to be abandoned.

**Table 5. Cycle outcome following PRP instillation (n = 40)**

| Outcome | n | % |
|---------|---|---|
|---------|---|---|

|                             |    |      |
|-----------------------------|----|------|
| Clinical pregnancy achieved | 6  | 15.0 |
| Not conceived               | 34 | 85.0 |
| Adverse events recorded     | 0  | 0.0  |

## 140 **DISCUSSION**

141 The central observation is straightforward: in women whose endometrium failed to develop  
 142 adequately on clomiphene citrate, two intrauterine instillations of autologous platelet-rich plasma  
 143 were followed by a mean increase of 2.33 mm, from 5.10 mm to 7.43 mm, carrying the group  
 144 mean across the 7 mm threshold conventionally regarded as compatible with implantation. The  
 145 effect was highly significant and was reproduced in every subgroup examined.

146 The magnitude of this change sits within the range described elsewhere. Chang and colleagues,  
 147 in the first published application, reported growth from approximately 5 mm to above 7 mm in  
 148 refractory thin endometrium during in vitro fertilisation.<sup>13</sup> Zadehmodarres and co-workers  
 149 observed a comparable increase in a pilot series,<sup>18</sup> and Tandulwadkar's group documented  
 150 similar gains before frozen embryo transfer.<sup>14</sup> Randomised evidence is broadly supportive:  
 151 Nazari and colleagues found significantly greater expansion with PRP than with standard  
 152 preparation,<sup>15</sup> and a recent meta-analysis concluded that PRP increases both thickness and  
 153 clinical pregnancy rates.<sup>19</sup>

154 What distinguishes this cohort is the context in which the endometrium was thin. Most published  
 155 work concerns hormonally prepared cycles for embryo transfer, where thinning reflects atrophy,  
 156 adhesions or previous instrumentation. Here the mechanism is pharmacological: clomiphene's  
 157 occupancy of endometrial oestrogen receptors is a functional, self-limiting blockade rather than  
 158 structural tissue loss.<sup>20</sup> A receptive substrate is therefore to be expected, and the near-uniform

response observed is consistent with that. The two studies closest in design support this reading. Morad and colleagues, in a self-controlled trial of PRP during clomiphene therapy, reported a comparable baseline thickness and a similar direction of change,<sup>16</sup> and Özyurt and co-workers, comparing clomiphene plus PRP against clomiphene alone, found significantly greater endometrial expansion in the PRP arm.<sup>17</sup>

Two features of the data deserve emphasis. First, the response was inversely related to baseline thickness: women beginning below 3 mm gained 4.35 mm, while those already between 5 and 7 mm gained 1.85 mm. Second, and consistent with this, the post-treatment values converged into a narrow band between roughly 7.0 and 7.8 mm across all twelve subgroups, even though pre-treatment means differed by nearly a millimetre and a half. Taken together these observations suggest that PRP does not add a fixed increment but rather restores the endometrium towards its physiological potential, with the greatest apparent benefit where the deficit is largest. This has an obvious practical corollary — the women most likely to gain are those currently considered least salvageable — though regression to the mean cannot be excluded as a partial explanation in an uncontrolled design and the subgroup with the thinnest endometrium contained only four participants.

The absence of any modifying effect from ovarian reserve, thyroid status, prolactin or body mass index is also noteworthy. Obesity is known to impair the response to ovulation induction,<sup>20</sup> yet obese participants here reached a post-treatment thickness indistinguishable from that of normal-weight women. This suggests the endometrial action of PRP is largely independent of the systemic endocrine milieu — plausible, since the growth factors are delivered directly to the target tissue and act locally.<sup>11,12</sup>

181 The clinical pregnancy rate of 15.0% is the least encouraging finding and requires candid  
182 interpretation. It is lower than several published series, and it demonstrates that thickening the  
183 endometrium is not synonymous with restoring receptivity. Thickness is a convenient  
184 sonographic proxy, but implantation depends additionally on vascularity, glandular maturation,  
185 molecular receptivity and embryo quality, none of which was assessed here. A structurally  
186 adequate but functionally unreceptive endometrium remains entirely possible, and the gap  
187 between the near-universal morphological response and the modest reproductive one is a useful  
188 corrective to over-interpretation of thickness alone.

189 Several limitations constrain these conclusions. The study was single-armed, so the contribution  
190 of PRP cannot be separated from that of the second clomiphene cycle or from spontaneous cycle-  
191 to-cycle variation. The sample of 40 was modest and drawn from a single centre, and follow-up  
192 ended at clinical pregnancy, leaving live birth unrecorded. PRP was not standardised to a defined  
193 platelet concentration, limiting reproducibility across centres. Endometrial thickness was  
194 measured transabdominally, which is less precise than the transvaginal approach.

195 Notwithstanding these caveats, the procedure was simple, inexpensive, performed in the  
196 outpatient setting and free of adverse effects. For women who ovulate satisfactorily yet cannot  
197 conceive, and whose alternative is escalation to gonadotrophins with their cost and risk of  
198 multiple pregnancy, an autologous intervention of this kind is attractive. Adequately powered  
199 randomised trials with standardised preparation and live birth as the endpoint are the necessary  
200 next step.

## CONCLUSION

Intrauterine instillation of autologous platelet-rich plasma produced a significant increase in endometrial thickness in women with a thin endometrium in clomiphene citrate-induced cycles, raising the group mean above the 7 mm threshold and benefiting every endocrine and anthropometric subgroup examined. The gain was greatest where the endometrium was thinnest. The intervention was safe, technically undemanding and well tolerated, but the modest clinical pregnancy rate indicates that improved thickness alone does not guarantee conception. Randomised controlled trials with standardised preparation protocols and live birth as the primary endpoint are needed before the technique can be recommended for routine use.

## REFERENCES

1. Hull MG, Glazener CM, Kelly NJ, Conway DI, Foster PA, Hinton RA, et al. Population study of causes, treatment, and outcome of infertility. *Br Med J (Clin Res Ed)*. 1985;291(6510):1693-7.
2. The ESHRE Capri Workshop Group. Health and fertility in World Health Organization type 2 anovulatory women. *Hum Reprod Update*. 2012;18(5):586-99.
3. Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, et al. Polycystic ovary syndrome: etiology, current management, and future therapeutics. *J Clin Med*. 2023;12(4):1454.
4. Brown J, Farquhar C. Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome. *Cochrane Database Syst Rev*. 2016;12(12):CD002249.

5. Homburg R. Clomiphene citrate—end of an era? A mini review. *Hum Reprod.* 2005;20(8):2043-51.
6. Roy KK, Baruah J, Singla S, Sharma JB, Singh N, Jain SK, et al. A prospective randomized trial comparing the efficacy of letrozole and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. *J Hum Reprod Sci.* 2012;5(1):20-5.
7. Kortam M, Abdelrahman R, Fateen H. L-carnitine and clomiphene citrate for induction of ovulation in women with polycystic ovary syndrome: randomized controlled trial. *Evid Based Womens Health J.* 2020;10(1):1-7.
8. Liao Z, Liu C, Cai L, Shen L, Sui C, Zhang H, et al. The effect of endometrial thickness on pregnancy, maternal, and perinatal outcomes of women in fresh cycles after IVF/ICSI: a systematic review and meta-analysis. *Front Endocrinol.* 2022;12:814648.
9. Hendawy SF, Samaha HE, Elkholy MF. Letrozole versus clomiphene citrate for induction of ovulation in patients with polycystic ovarian syndrome undergoing intrauterine insemination. *Clin Med Insights Reprod Health.* 2011;5:11-6.
10. Wang Y, Tang Z, Teng X. New advances in the treatment of thin endometrium. *Front Endocrinol.* 2024;15:1269382.
11. Samy A, Abbas AM, Elmoursi A, Elsayed M, Hussein RS. Effect of autologous platelet-rich plasma transfusion in the treatment of infertile women with thin endometrium and its implications in IVF cycles: a literature review. *Middle East Fertil Soc J.* 2020;25:5.

- 240 12. Molina A, Sánchez J, Sánchez W, Vielma V. Platelet-rich plasma as an adjuvant in the  
241 endometrial preparation of patients with refractory endometrium. *JBRA Assist Reprod.*  
242 2018;22(1):42-8.
- 243 13. Chang Y, Li J, Chen Y, Wei L, Yang X, Shi Y, et al. Autologous platelet-rich plasma  
244 promotes endometrial growth and improves pregnancy outcome during in vitro  
245 fertilization. *Int J Clin Exp Med.* 2015;8(1):1286-90.
- 246 14. Tandulwadkar SR, Naralkar MV, Surana AD, Selvakarthick M, Kharat AH. Autologous  
247 intrauterine platelet-rich plasma instillation for suboptimal endometrium in frozen  
248 embryo transfer cycles: a pilot study. *J Hum Reprod Sci.* 2017;10(3):208-12.
- 249 15. Nazari L, Salehpour S, Hoseini S, Zadehmodarres S, Azargashb E. Effects of autologous  
250 platelet-rich plasma on endometrial expansion in patients undergoing frozen-thawed  
251 embryo transfer: a double-blind RCT. *Int J Reprod Biomed.* 2019;17(6):443-8.
- 252 16. Morad A, Elgendy H, Assar T. Autologous platelet-rich plasma to prevent a thin  
253 endometrium in patients undergoing clomiphene citrate therapy: a pilot prospective self-  
254 controlled trial. *Evid Based Womens Health J.* 2021;11(1):10-6.
- 255 17. Özyurt R, Bulutlar E, Yılmaz MB. Autologous platelet-rich plasma intrauterine perfusion  
256 improves the fertility outcome by correcting the thin endometrium due to clomiphene  
257 citrate. *Med J Bakirkoy.* 2024;20(1):72-8.
- 258 18. Zadehmodarres S, Salehpour S, Saharkhiz N, Nazari L. Treatment of thin endometrium  
259 with autologous platelet-rich plasma: a pilot study. *JBRA Assist Reprod.* 2017;21(1):54-  
260 6.



- 261 19. Liu X, Qian C, Jiang X, Zhou Y, Feng X, Ding Y, et al. Efficacy of platelet-rich plasma  
262 in the treatment of thin endometrium: a meta-analysis of randomized controlled trials.  
263 BMC Pregnancy Childbirth. 2024;24(1):567.
- 264 20. Balen AH, Platteau P, Andersen AN, Devroey P, Sørensen P, Helmgaard L, et al. The  
265 influence of body weight on response to ovulation induction with gonadotrophins in 335  
266 women with WHO group II anovulatory infertility. BJOG. 2006;113(10):1195-202.